Insulin Therapy

ApprovedSmall molecule

Sanofi

Insulin Therapy is one of 636 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

397

Total Trials

Active Trials

635

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Diabetic KetoacidosisActive, not recruiting

Varicose UlcerActive, not recruiting

ToxicityActive, not recruiting

Gestational DiabetesActive, not recruiting

Cognitive ImpairmentActive, not recruiting

StrokeActive, not recruiting

Insulin SecretionActive, not recruiting

Down SyndromeActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Diabetic KetoacidosisPhase 2

Active, not recruiting

Varicose UlcerPhase 3

Active, not recruiting

ToxicityApproved

Active, not recruiting

Gestational DiabetesPhase 2

Active, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

StrokePhase 3

Active, not recruiting

Insulin SecretionPreclinical

Active, not recruiting

Down SyndromePhase 1

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Showing 10 of 25 indications

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Insulin Therapy

Byetta

55 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Glargine

Eli Lilly

Preclinical

8 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Lovaza

AstraZeneca

Preclinical

1 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Study completion

NCT05098470

Q4 2027

Post-ApprovalNot yet recruiting

Type 2 Diabetes

NCT07173712

Clinical

Trials by Indication[1]

Type 2 Diabetes59 trials

Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)

Terminated· Sanofi logo

Sanofi·Phase 4·NCT00627471·9 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00331851·584 enrolled

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02030600·721 enrolled

Show 56 more trials

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02942914·80 enrolled

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00982644·1,030 enrolled

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03951805·205 enrolled

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Not yet recruiting·YYanbing Li·Phase 4·NCT07173712·324 enrolled

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00360334·235 enrolled

A Study for Patients With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01027871·289 enrolled

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 4·NCT03087032·164 enrolled

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment

Completed· Sanofi logo

Sanofi·Phase 4·NCT02967237·136 enrolled

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT01123980·521 enrolled

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT04093752·917 enrolled

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00598793·242 enrolled

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00097877·293 enrolled

A Study of LY3209590 in Participants With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03367377·70 enrolled

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs

Completed· Sanofi logo

Sanofi·Phase 4·NCT01203111·207 enrolled

Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

Completed· Sanofi logo

Sanofi·Phase 3·NCT01353469·485 enrolled

Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes

Completed· Sanofi logo

Sanofi·Phase 4·NCT01127269·178 enrolled

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT03730662·2,002 enrolled

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00641056·467 enrolled

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Completed· Sanofi logo

Sanofi·Phase 3·NCT03798080·426 enrolled

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Completed· Sanofi logo

Sanofi·Phase 4·NCT00941369·345 enrolled

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03751657·247 enrolled

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00510952·471 enrolled

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Completed·PPopulation Health Research Institute·Phase 3·NCT03130426·161 enrolled

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02906917·532 enrolled

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01059799·435 enrolled

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT06688123·275 enrolled

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00824668·24 enrolled

Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Completed·PPopulation Health Research Institute·Phase 4·NCT01181674·83 enrolled

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00097084·324 enrolled

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00082381·551 enrolled

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Completed·FFudan University·Phase 4·NCT02303730·76 enrolled

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Completed· Sanofi logo

Sanofi·Phase 3·NCT03798054·878 enrolled

Insulin Glargine in Type 2 Diabetes

Completed· Sanofi logo

Sanofi·Phase 4·NCT00268645·534 enrolled

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Completed· Sanofi logo

Sanofi·Phase 4·NCT00174681·390 enrolled

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine

Completed· Sanofi logo

Sanofi·Phase 4·NCT00518427·26 enrolled

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05013229·679 enrolled

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01076647·467 enrolled

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00184613·22 enrolled

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01796366·40 enrolled

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

Completed· Sanofi logo

Sanofi·Phase 4·NCT02606357·242 enrolled

Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT00641407·100 enrolled

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00377858·484 enrolled

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00355849·555 enrolled

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01865292·40 enrolled

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Completed· Sanofi logo

Sanofi·Phase 3·NCT02855684·604 enrolled

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT04153981·304 enrolled

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Completed· Sanofi logo

Sanofi·Phase 3·NCT02752828·521 enrolled

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01819129·881 enrolled

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Completed· Sanofi logo

Sanofi·Phase 2·NCT01596504·142 enrolled

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05803421·2,749 enrolled

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04262661·36 enrolled

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02470039·50 enrolled

A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04136067·36 enrolled

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00279201·2,091 enrolled

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00437112·142 enrolled

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT02408120·226 enrolled

Type 2 Diabetes Mellitus36 trials

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05702073·423 enrolled

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT06370715·150 enrolled

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01175811·402 enrolled

Show 33 more trials

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Completed· Sanofi logo

Sanofi·Phase 4·NCT02954692·112 enrolled

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03078478·1,609 enrolled

Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus

Completed·UUniversity of Guadalajara·Phase 4·NCT02680457·12 enrolled

Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 4·NCT01169818·555 enrolled

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01682759·751 enrolled

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care

Terminated· Sanofi logo

Sanofi·Phase 4·NCT00950534·25 enrolled

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Completed·LLexicon Pharmaceuticals·Phase 3·NCT03285594·571 enrolled

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Terminated· Roche logo

Roche·Phase 3·NCT01051011·370 enrolled

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02501161·1,012 enrolled

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 4·NCT05114590·124 enrolled

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT02401243·253 enrolled

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

Completed· Sanofi logo

Sanofi·Phase 4·NCT01212913·161 enrolled

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

Completed· Sanofi logo

Sanofi·Phase 4·NCT04980027·228 enrolled

LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi··NCT00423215·1,007 enrolled

A Study in Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01468987·1,369 enrolled

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Completed· Sanofi logo

Sanofi·Phase 3·NCT02294474·505 enrolled

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 3·NCT04460326·137 enrolled

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Completed· Sanofi logo

Sanofi·Phase 4·NCT05002933·570 enrolled

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

Completed· Sanofi logo

Sanofi·Phase 3·NCT02585674·151 enrolled

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05596747·31 enrolled

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01135992·143 enrolled

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Completed· Sanofi logo

Sanofi·Phase 3·NCT02752412·513 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT01689142·240 enrolled

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

Completed· Pfizer logo

Pfizer·Phase 4·NCT00418522·413 enrolled

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02420262·506 enrolled

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Terminated· Sanofi logo

Sanofi·Phase 3·NCT03434119·241 enrolled

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02773368·420 enrolled

Insulin Glargine in Type 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 4·NCT00311818

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00935532·427 enrolled

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

Terminated· Sanofi logo

Sanofi·Phase 4·NCT05552859·62 enrolled

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Completed· Sanofi logo

Sanofi·Phase 4·NCT02738151·929 enrolled

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.

Completed· Sanofi logo

Sanofi·Phase 4·NCT01122979·72 enrolled

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01648582·774 enrolled

Type 1 Diabetes17 trials

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01769404·25 enrolled

Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.

Unknown status·MMedical University of Warsaw·Phase 4·NCT02685449·70 enrolled

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT03740919·751 enrolled

Show 14 more trials

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

Completed· Sanofi logo

Sanofi·Phase 3·NCT00046150·59 enrolled

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01730014·70 enrolled

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01704417·40 enrolled

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03965013·78 enrolled

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

Completed·SSansum Diabetes Research Institute·Phase 4·NCT03668808·25 enrolled

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01497574·32 enrolled

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01784211·76 enrolled

A Study of LY900014 in Participants With Type 1 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT03214367·1,392 enrolled

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00127634·385 enrolled

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01079234·493 enrolled

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01114542·66 enrolled

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00961324·54 enrolled

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

Completed·TTonghua Dongbao Pharmaceutical Co.,Ltd·Phase 3·NCT07282054·550 enrolled

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Completed· Sanofi logo

Sanofi·Phase 3·NCT01223131·162 enrolled

Type 1 Diabetes Mellitus16 trials

Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT01053728·46 enrolled

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT00883558·48 enrolled

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 1·NCT01676233·20 enrolled

Show 13 more trials

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 4·NCT00964574·68 enrolled

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 1·NCT01838083·50 enrolled

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT02735044·463 enrolled

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed· Sanofi logo

Sanofi·Phase 3·NCT03874715·210 enrolled

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 1·NCT01493115·18 enrolled

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT01194245·135 enrolled

Insulin Glargine in Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT00272090·489 enrolled

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01868529·63 enrolled

Dose-Exposure-Response in Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 1·NCT00368394·18 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT01689129·243 enrolled

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed· Sanofi logo

Sanofi·Phase 3·NCT02273180·507 enrolled

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02220296·62 enrolled

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Completed· Sanofi logo

Sanofi·Phase 3·NCT00115570·572 enrolled

Diabetes Mellitus7 trials

OPAL - Insulin Glulisine, Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT00272012·396 enrolled

Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)

Completed· Sanofi logo

Sanofi·Phase 4·NCT00390728·2,346 enrolled

The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing

Completed· Sanofi logo

Sanofi·Phase 4·NCT00609895·22 enrolled

Show 4 more trials

Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)

Completed· Sanofi logo

Sanofi·Phase 4·NCT00659477·117 enrolled

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00135941·582 enrolled

Insulin Glulisine, Diabetes Mellitus Type 1

Completed· Sanofi logo

Sanofi·Phase 3·NCT00397553·104 enrolled

SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1

Completed· Sanofi logo

Sanofi·Phase 4·NCT00313937·91 enrolled

35 more indications

Type 2 Diabetic Patients4 trials

Insulin Glulisine in Type 2 Diabetic Patients

Completed· Sanofi logo

Sanofi·Phase 4·NCT00360698·106 enrolled

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Completed· Roche logo

Roche·Phase 3·NCT00755287·1,072 enrolled

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT02453685·335 enrolled

Show 1 more trial

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Completed· Sanofi logo

Sanofi·Phase 2·NCT01476475·323 enrolled

MPA4 trials

The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.

Completed·MMedical University of Warsaw·Phase 4·NCT04124302·76 enrolled

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

Completed·UUniversity of Washington·Phase 4·NCT04623086·59 enrolled

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study

Completed· Sanofi logo

Sanofi·Phase 4·NCT01121835·934 enrolled

Show 1 more trial

A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02152384·28 enrolled

Efficacy and Safety4 trials

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Terminated·MMannkind Corporation·Phase 3·NCT01196104·39 enrolled

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Completed· Sanofi logo

Sanofi·Phase 3·NCT02058147·1,170 enrolled

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01175824·478 enrolled

Show 1 more trial

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

Completed· Pfizer logo

Pfizer·Phase 4·NCT00391027·261 enrolled

Trial3 trials

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01809184·84 enrolled

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01597713·83 enrolled

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02479022·84 enrolled

Outcome2 trials

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00069784·12,537 enrolled

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

Completed· Sanofi logo

Sanofi·Phase 4·NCT00565162·124 enrolled

Adolescent2 trials

Apidra Children & Adolescents Study

Completed· Sanofi logo

Sanofi·Phase 4·NCT01202474·100 enrolled

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Completed·YYale University·Phase 1·NCT03400501·32 enrolled

Metformin2 trials

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Completed· Sanofi logo

Sanofi·Phase 3·NCT01336751·212 enrolled

Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects

Completed·GGWT-TUD GmbH·Phase 4·NCT00857870·96 enrolled

ART2 trials

Self Titration With Apidra to Reach Target Study (START)

Completed· Sanofi logo

Sanofi·Phase 4·NCT01013571·493 enrolled

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Completed· Sanofi logo

Sanofi·Phase 3·NCT05413369·582 enrolled

Effectiveness2 trials

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Completed·TTehran University of Medical Sciences·Phase 4·NCT01832935·200 enrolled

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis

Completed·TThe University of Texas Health Science Center, Houston·N/A·NCT02006342·40 enrolled

Type 1 Diabetic2 trials

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01002768·28 enrolled

Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls

Completed·VVanderbilt University·N/A·NCT00927524·24 enrolled

Endothelial Function2 trials

Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study

Unknown status·Iikfe-CRO GmbH·Phase 4·NCT01417897·12 enrolled

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

Completed·UUniversity of Palermo·Phase 4·NCT05360537·100 enrolled

Treatment2 trials

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01894568·388 enrolled

Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL

Completed· Sanofi logo

Sanofi·Phase 4·NCT03406000·170 enrolled

Non-Diabetic Patients1 trial

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Completed·EEmory University·Phase 4·NCT02443402·68 enrolled

Oxidative Stress1 trial

Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT02526810·70 enrolled

GIST1 trial

APIDRA Registration Study

Completed· Sanofi logo

Sanofi·Phase 4·NCT00489190·45 enrolled

ESS1 trial

Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control

Completed· Sanofi logo

Sanofi·Phase 4·NCT00701831·241 enrolled

Insulin Secretion1 trial

Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes

Completed·RRuhr University of Bochum·Phase 4·NCT01249677·14 enrolled

Down syndrome1 trial

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Completed·HHealthPartners Institute·Phase 1·NCT02432716·12 enrolled

Pemphigus1 trial

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions

Completed·—·Phase 2·NCT07461103·20 enrolled

Function1 trial

Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)

Completed· Sanofi logo

Sanofi·Phase 4·NCT00562172·75 enrolled

Monotherapy1 trial

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Completed· Sanofi logo

Sanofi·Phase 4·NCT00384215·352 enrolled

Safety and Efficacy1 trial

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Completed· Sanofi logo

Sanofi·Phase 3·NCT02320721·1,014 enrolled

GLP-11 trial

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Completed·UUniversity of Washington·Phase 4·NCT01524705·102 enrolled

Efficacy1 trial

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin

Completed· Sanofi logo

Sanofi·Phase 4·NCT02967211·609 enrolled

Intravenous1 trial

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

Completed·NNorthwestern University·Phase 4·NCT00338104·75 enrolled

Stroke1 trial

Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke

Unknown status·NNational Taiwan University Hospital·Phase 3·NCT02607943·120 enrolled

Memory1 trial

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

Completed·HHealthPartners Institute·Phase 2·NCT01436045·12 enrolled

Diabetic Retinopathy1 trial

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

Completed· Sanofi logo

Sanofi·Phase 4·NCT00174824·1,024 enrolled

Cardiovascular1 trial

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Unknown status·Iikfe-CRO GmbH·Phase 4·NCT01500850·60 enrolled

Diabetic Ketoacidosis1 trial

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Terminated·HHealthPartners Institute·Phase 2·NCT06007508·8 enrolled

ST Elevation Myocardial Infarction1 trial

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00670228·34 enrolled

Toxicity1 trial

Empagliflozin Effect on Glucose Toxicity

Withdrawn·UUniversity Hospital Tuebingen·Phase 4·NCT03437330

Coronary Artery Disease1 trial

Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)

Unknown status·MMunich Municipal Hospital·Phase 4·NCT01035528·32 enrolled

Obese1 trial

Insulin Glulisine in Healthy Lean and Obese Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT00311077

Unspecified12 trials

Safety of NNC 0123-0000-0338 in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01334034·70 enrolled

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Terminated·WWeill Cornell Medical College in Qatar·Phase 4·NCT03349840·273 enrolled

Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

Completed·MMedical University of Vienna·Phase 3·NCT02168491·10 enrolled

Show 9 more trials

Insulin Glargine During and After the Period of Fasting in Ramadan

Completed· Sanofi logo

Sanofi·Phase 4·NCT00258804·450 enrolled

DOMME Dose Optimization Multicentric Mexican Evaluation

Completed· Sanofi logo

Sanofi·Phase 4·NCT00488527·371 enrolled

Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement

Completed· Sanofi logo

Sanofi·Phase 4·NCT00354939·480 enrolled

LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous

Completed· Sanofi logo

Sanofi·Phase 4·NCT00322075·35 enrolled

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 3·NCT05098470·100 enrolled

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy

Completed· Sanofi logo

Sanofi·Phase 3·NCT00174642·811 enrolled

Normal Versus Dual Wave Insulin Bolus for High-protein Food

Completed·MMedical University of Warsaw·Phase 4·NCT02276859·70 enrolled

Effect of LIXIsenatide on the Renal System

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT02276196·40 enrolled

Extension to Study HMR1964A/3011 in Belgium

Completed· Sanofi logo

Sanofi·Phase 4·NCT00576862·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 397 trial records for Insulin Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insulin Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insulin Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Insulin Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Trials by Indication[1]

Type 2 Diabetes59 trials

Type 2 Diabetes Mellitus36 trials

Type 1 Diabetes17 trials

Type 1 Diabetes Mellitus16 trials

Diabetes Mellitus7 trials

Type 2 Diabetic Patients4 trials

MPA4 trials

Efficacy and Safety4 trials

Trial3 trials

Outcome2 trials

Adolescent2 trials

Metformin2 trials

ART2 trials

Effectiveness2 trials

Type 1 Diabetic2 trials

Endothelial Function2 trials

Treatment2 trials

Non-Diabetic Patients1 trial

Oxidative Stress1 trial

GIST1 trial

ESS1 trial

Insulin Secretion1 trial

Down syndrome1 trial

Pemphigus1 trial

Function1 trial

Monotherapy1 trial

Safety and Efficacy1 trial

GLP-11 trial

Efficacy1 trial

Intravenous1 trial

Stroke1 trial

Memory1 trial

Diabetic Retinopathy1 trial

Cardiovascular1 trial

Diabetic Ketoacidosis1 trial

ST Elevation Myocardial Infarction1 trial

Toxicity1 trial

Coronary Artery Disease1 trial

Obese1 trial

Unspecified12 trials

References

Drug Info

Quick Facts

Related News